The National institutes of Health (NIH), through the Rare Diseases Clinical Research Consortia (RDCRC), has awarded a research team from Yale University, George Washington University, and Duke University $7.8 million to establish a rare disease network for myasthenia gravis (MGNet).
Characterized by weakness and rapid fatigue of any of the muscles under voluntary control reports YaleNews’ Bill Hathaway. The symptoms of Myasthenia can range from arm and leg muscle weakness to double vision, drooping eyelids and difficulties with speech, chewing, swallowing and even breathing.
Seven Study Sites
This new Myasthenia network will include a network that involves 7 study sites and ultimately be part of 25 established NIH RDCRCs (NCATS Rare Disease Network). The network will also include basic and clinical investigators, patient advocacy groups, and biotechnology and pharmaceutical companies collaborating to enhance therapeutic research and development in the rare disease segment.
The Principal Investigators
Kevin C. O’Connor, Yale University
Richard J. Nowak, Yale University
Linda Kusner, George Washington University
Jeffrey T. Guptill, Duke University